このエントリーをはてなブックマークに追加
ID 60775
フルテキストURL
著者
Tetsunaga, Tomoko Department of Orthopedic Surgery, Okayama University Hospital
Tetsunaga, Tomonori Department of Orthopedic Surgery, Okayama University Hospital ORCID Kaken ID
Nishida, Keiichiro Department of Orthopedic Surgery, Okayama University Hospital Kaken ID publons researchmap
Misawa, Haruo Department of Orthopedic Surgery, Okayama University Hospital Kaken ID publons researchmap
Takigawa, Tomoyuki Department of Orthopedic Surgery, Okayama University Hospital ORCID Kaken ID researchmap
Yamane, Kentaro Department of Orthopedic Surgery, Okayama University Hospital
Tsuji, Hironori Department of Orthopedic Surgery, Okayama University Hospital
Takei, Yoshitaka Department of Orthopedic Surgery, Kurashiki Municipal Hospital
Ozaki, Toshifumi Department of Orthopedic Surgery, Okayama University Hospital Kaken ID publons researchmap
抄録
Background
Mirogabalin, which is approved for the treatment of peripheral neuropathic pain in Japan, is a ligand for the α2δ subunit of voltage-gated calcium channels. Both pregabalin and mirogabalin act as nonselective ligands at the α2δ-1 and α2δ-2 subunits. Mirogabalin has a unique binding profile and long duration of action. Pregabalin has been reported to produce intolerable adverse effects in some patients. This study investigated outcomes associated with mirogabalin administration in patients with peripheral neuropathic pain who ceased treatment with pregabalin.
Methods
We retrospectively assessed peripheral neuropathic pain using the neuropathic pain screening questionnaire (NeP score) in 187 patients (58 men, 129 women) who were treated with mirogabalin. All patients had switched from pregabalin to mirogabalin due to lack of efficacy or adverse events. Differences in the treatment course (i.e., numeric rating scale (NRS) scores) were compared using one-way analysis of variance with Bonferroni post hoc tests.
Results
The mean age of the patients was 72.3 years (range, 30–94 years), and the mean duration of disease was 37 months (range, 3–252 months). After treatment with mirogabalin for 1 week, NRS scores significantly decreased compared with baseline and continued to decrease over time. After 8 weeks, NRS scores improved by ≥ 30% from baseline in 113 patients (69.3%). Twenty-four patients (12.8%) stopped mirogabalin treatment due to adverse events. Somnolence (26.7%), dizziness (12.3%), edema (5.9%), and weight gain (0.5%) were noted as adverse events of mirogabalin.
Conclusions
The results of this investigation indicate that mirogabalin is safe and effective for reducing peripheral neuropathic pain.
キーワード
Peripheral neuropathic pain
Mirogabalin
Pregabalin
Adverse event
発行日
2020-05-26
出版物タイトル
Journal of Orthopaedic Surgery and Research
15巻
1号
出版者
Springer
開始ページ
191
ISSN
1749-799X
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1186/s13018-020-01709-3
ライセンス
http://creativecommons.org/licenses/by/4.0/